Cargando…
A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer
BACKGROUND: Patients with metastatic colorectal cancer (mCRC) often suffer from progressive disease despite previous therapy. It has been a great challenge for those patients. In 2012, regorafenib was approved for mCRC. In this meta-analysis, we aimed to collect and present existing data to exploret...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer Health
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200445/ https://www.ncbi.nlm.nih.gov/pubmed/30290640 http://dx.doi.org/10.1097/MD.0000000000012635 |